CDK4/6 Targeting May Be Effective in Acquired BRAF Plus MEK Inhibitor–Resistant Melanoma AJMC, 25 Sep 2021 A preclinical study published in Molecular Cancer Therapy identified the combination of CDK4/6 and MEK inhibitors as a…